These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 12738352)

  • 21. Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers.
    Mendelson J; Jones RT; Welm S; Baggott M; Fernandez I; Melby AK; Nath RP
    Psychopharmacology (Berl); 1999 Jan; 141(1):37-46. PubMed ID: 9952063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sleep-disordered breathing in patients with opioid use disorders in long-term maintenance on buprenorphine-naloxone: A case series.
    DeVido J; Connery H; Hill KP
    J Opioid Manag; 2015; 11(4):363-6. PubMed ID: 26312963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films.
    Strain EC; Harrison JA; Bigelow GE
    Clin Pharmacol Ther; 2011 Mar; 89(3):443-9. PubMed ID: 21270789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sublingual buprenorphine-naloxone precipitated withdrawal-A case report with review of literature and clinical considerations.
    Bhatia G; Sarkar S
    Asian J Psychiatr; 2020 Oct; 53():102121. PubMed ID: 32460142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of the newer class of opioid antagonists in pregnancy.
    Poon S; Pupco A; Koren G; Bozzo P
    Can Fam Physician; 2014 Jul; 60(7):631-2, e348-9. PubMed ID: 25022635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.
    Fudala PJ; Bridge TP; Herbert S; Williford WO; Chiang CN; Jones K; Collins J; Raisch D; Casadonte P; Goldsmith RJ; Ling W; Malkerneker U; McNicholas L; Renner J; Stine S; Tusel D;
    N Engl J Med; 2003 Sep; 349(10):949-58. PubMed ID: 12954743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia.
    Horyniak D; Dietze P; Larance B; Winstock A; Degenhardt L
    Int J Drug Policy; 2011 Mar; 22(2):167-71. PubMed ID: 21112758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Buprenorphine-naloxone buccal soluble film for the treatment of opioid dependence: current update.
    Soyka M
    Expert Opin Drug Deliv; 2015 Feb; 12(2):339-47. PubMed ID: 25156759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of buprenorphine/naloxone maintenance treatment on sexual dysfunction, sleep and weight in opioid use disorder patients.
    Baykara S; Alban K
    Psychiatry Res; 2019 Feb; 272():450-453. PubMed ID: 30611963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years.
    Fiellin DA; Moore BA; Sullivan LE; Becker WC; Pantalon MV; Chawarski MC; Barry DT; O'Connor PG; Schottenfeld RS
    Am J Addict; 2008; 17(2):116-20. PubMed ID: 18393054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Buprenorphine alone or with naloxone: Which is safer?
    Kelty E; Cumming C; Troeung L; Hulse G
    J Psychopharmacol; 2018 Mar; 32(3):344-352. PubMed ID: 29433352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of conventional, complementary, and alternative treatments for pain among individuals seeking primary care treatment with buprenorphine-naloxone.
    Barry DT; Savant JD; Beitel M; Cutter CJ; Moore BA; Schottenfeld RS; Fiellin DA
    J Addict Med; 2012 Dec; 6(4):274-9. PubMed ID: 23041680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Can the chronic administration of the combination of buprenorphine and naloxone block dopaminergic activity causing anti-reward and relapse potential?
    Blum K; Chen TJ; Bailey J; Bowirrat A; Femino J; Chen AL; Simpatico T; Morse S; Giordano J; Damle U; Kerner M; Braverman ER; Fornari F; Downs BW; Rector C; Barh D; Oscar-Berman M
    Mol Neurobiol; 2011 Dec; 44(3):250-68. PubMed ID: 21948099
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medication-Assisted Treatment of Opioid Use Disorder in Adolescents and Young Adults.
    Cottrill CB; Matson SC
    Adolesc Med State Art Rev; 2014 Aug; 25(2):251-65. PubMed ID: 27132312
    [No Abstract]   [Full Text] [Related]  

  • 35. Drugs approved for opiate dependence.
    FDA Consum; 2003; 37(1):6. PubMed ID: 12625293
    [No Abstract]   [Full Text] [Related]  

  • 36. Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals.
    Law FD; Diaper AM; Melichar JK; Coulton S; Nutt DJ; Myles JS
    J Psychopharmacol; 2017 Aug; 31(8):1046-1055. PubMed ID: 28631527
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anesthesia for patients on buprenorphine.
    Bryson EO; Lipson S; Gevirtz C
    Anesthesiol Clin; 2010 Dec; 28(4):611-7. PubMed ID: 21074741
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Buprenorphine and naloxone for heroin dependence.
    Johnson RE; McCagh JC
    Curr Psychiatry Rep; 2000 Dec; 2(6):519-26. PubMed ID: 11123005
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market.
    Bruce RD; Govindasamy S; Sylla L; Kamarulzaman A; Altice FL
    Am J Drug Alcohol Abuse; 2009; 35(2):68-72. PubMed ID: 19212931
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Case series on the safe use of buprenorphine/naloxone in individuals with acute hepatitis C infection and abnormal hepatic liver transaminases.
    Bruce RD; Altice FL
    Am J Drug Alcohol Abuse; 2007; 33(6):869-74. PubMed ID: 17994482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.